Circadian distribution of serum cytokines in multiple sclerosis

Clinica Terapeutica

Volumn 158, Issue 2, 2007, Pages 157-162

  Kanabrocki, E L ^a,b   Ryan, M D ^b   Lathers, D ^b   Achille, N ^b   Young, M R I ^b   Cauteren, J V ^b   Foley, S ^b   Johnson, M C ^b   Friedman, N C ^a   Siegel, G ^b   Nemchausky, B A ^c  

^a Nuclear Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

GM CSF; IL 10; IL 2; IL 6; INF; Multiple sclerosis; Tnf

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; PURINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PROTEIN DIET;

ADULT; AGED; CIRCADIAN RHYTHM; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 34248179512     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Liew FY. T-cell subsets and cytokines in parasitic infections. Immunology Today 1992; 13:445-5
2. Imitola J, Chitnis T, Khoury SJ. Cytokines in Multiple Sclerosis: from bench to bed side. Pharmacol Ther 2005; 106(2), 163-77
3. Kraus J, Kuehne BS, Tofighi H, et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis Acta Neurol Scand 2002; 105(4):300-8
4. Touitou Y, Portaluppi F, Smolensky MH, et al. Ethical principles and standards for the conduct of human and animal biological rhythm research. Chronobiol.Int 2004; 21(1): 161-70
5. Sothern R, Roitman-Johnson B, Kanabrocki EL, et al. Circadian characteristcs of Interleukin-6 in blood and urine of clinically healthy men. In Vivo 1995; 9:331-9
6. Oppenheim JJ, Feldmann M. Introduction to the Role of Cytokines in Innate Host Defense and Adaptive Immunity. In: JJ Oppenheim, M Feldmann, Eds. Cytokine References. Academic Press, 2001; 3-20
7. Robb RJ, Smith KA. Heterogeneity of human T-cell growth factor(s) due to variable glycosylation. Mol Immunol 1981; 18:1087-94
8. Gallo P, Piccino M, Pagni S, et al. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1988; 24:795-7
9. Oehninger-Gatti C, Buzo R, Alcantara JC, et al. The use of biological markers in the diagnosis and follow-up of patients with multiple sclerosis. Test of the five humours. Rev Neurol 2000; 30(10):977-9
10. Aboulgher MA. Mansour RT, Serour GI, et al. Elevated levels of interleukin-2, soluble interleukin-6 receptor and vacular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obst Gynecol Reprod Biol 1999; 87(1):81-5
11. Young MRI, Matthew JP, Kanabrocki EL, et al. Circadian rhythmometry of serum Interleukin-2, Interleukin-10, Tumor Necrosis Factor-α, and Granulocyte-Macrophage Colony-Stimulating Factor in men. Chronobiol Int 1995; 12(1):19-27
12. Kanabrocki EL, McCormick JB, Hermida RC, et al. Circadian interrelationship between serum uric acid and nitric oxide in adult male subjects. JAMA 2000: 283:2240-1
13. Spangelo BL, MacLeod RM, Isakson PC Production of interleukin-6 by anterior pituitary cells in vitro. Endocrinology 1990; 126:582-6
14. Gruol LD, Nelson ET. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997; 15:307-39
15. Gabriel AS, Ahnve S, Wretlind B, et al. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Int Med 2000; 248(1):61-6
16. Greig PC, Murtha AP, Jimmerson CJ, et al. Maternal serum IL-6 during pregnancy and during term and pre-term labor. Obst Gynecol 1997; 90(3):465-9
17. Rohde T, MacLean DA, Richter EA, et al. Prolonged submaximal eccentric exercise is associated with increased levels of plasma IL-6. Am J Physiol 1997; 273(Pt 1):E 85-91
18. Kado S, Nagase T, Nagta N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 1999; 36(1):67-72
19. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression. J Neurol 1996; 243(1):13-7
20. Baquai R, Kazmi SU, Qureshi H. Role of cytokines in giardiasis. J Pakistan Med Ass 2000; 50(4):113-5
21. Nicola NA: GM-CSF. In: JJ Oppenheim, M Feldmann, Eds. Cytokine References. Academic Press, 2001; 899-910
22. Aggarwal BB, Samanta A, Feldmann M: TNF-α. In: JJ Oppenheim, M Feldmann, Eds. Cytokine References. Academic Press, 2001; 413-34
23. Warzocha K, Salles G, Bienvenu J, et al. Prognostic significance of TNF-alpha and its p55 soluble receptor in malignant lymphomas. Leukemia 1997; 11(Suppl 3):441-3
24. Billiau A, Vandenbroeck K. IFN-γ. In: JJ Oppenheim, M Feldmann, Eds. Cytokine References. Academic Press, 2001; 641-88
25. Sheen-Chen SM, Chen WJ, et al. Serum concentration f tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43(3):21-5